Detail for MEK1


Full Name

Dual specificity mitogen-activated protein kinase kinase 1(MAPKK1)

Uniprot ID

Gene Name

MAP2K1

NCBI ID

Related Disease

  • Breast Cancer [ref.1]
  • Colon Cancer [ref.2]

Therapy Method

Function

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.

Related Pathway/CSCs feature

Reference

  • [1] EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling.
    Chang, C. J., et al. (2011). Cancer Cell 19(1): 86-100.. [ 21215703 ]
  • [2] EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.
    Feng, Y., et al. (2012). Cell Prolif 45(5): 413-419.. [ 22925500 ]

Back to top